Scienza e Tecnologia
Oncolytics Biotech® to Participate in Virtual Fireside Chat at the Canaccord Genuity 41st Annual Growth Conference
Dr. Matt Coffey, President & Chief Executive Officer of Oncolytics Biotech Inc.
Thursday, August 12, 2021
1:30 p.m. Eastern Daylight Time
Please click here
The Company will also be participating in one-on-one investor meetings at the conference. To schedule a meeting, please contact your Canaccord Genuity representative or email jpatton@oncolytics.ca.
A live webcast of the fireside chat will also be available on the Investor Relations page of Oncolytics' website (LINK) and will be archived for 90 days.
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it advances towards a registration study in metastatic breast cancer. For further information, please visit: www.oncolyticsbiotech.com.
Director of IR & Communication
+1-858-886-7813
jpatton@oncolytics.ca
LifeSci Advisors
+1-917-679-9282
tim@lifesciadvisors.com
Logo - https://mma.prnewswire.com/media/1064079/Oncolytics_Logo.jpg